Lobe Sciences Ltd. LOBEF
0.03 USD 0.00 (-5.57%)
At closeNov 11, 2026, 4:00 PM EST
0.028 Day range 0.0288
0.0021 52-week range 0.0629
- YTD
- +697.06%
- 1 year
- +674.29%
News
accessnewswire.com Lobe Sciences Appoints Tracy L. Goeken, M.D. Physician executive brings clinical development and regulatory experience in generalized anxiety disorder and sickle cell disease Company also engages Independent Trading Group (ITG) to provide…
accessnewswire.com Lobe Sciences Appoints Annette Grimaldi, Former Head of Life Sciences Investment Banking at BMO Capital Markets, to Board of Directors Executive with three decades of life sciences financing and M&A experience joins the board as Lobe advances L-130 in anxiety and cluster headache and S-100 in sickle cell disease VANCOUVER, BC /…
accessnewswire.com Lobe Sciences Announces Proposed Capital Markets Initiatives to Support Planned Growth Company intends to initiate independent market-making services, expanded investor and media outreach, and add board expertise in Canadian and U.S. capital markets VANCOUVER, BC / ACCESS Newswire /…
accessnewswire.com Lobe Sciences to Present Low-Dose L-130 Clinical Data at 9th Neuropsychiatric Drug Development Summit ● Dr. Frederick D. Sancilio to present "Reimagining Psychedelic Therapeutics for Daily Outpatient Use: Advancing Low-Dose Psilocin Beyond the Hallucinogenic Paradigm" on Wednesday, September 16 ●…
newsfilecorp.com Lobe Sciences to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto Vancouver, British Columbia--(Newsfile Corp. - September 14, 2026) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (FSE: LOBE.F) ("Lobe" or the "Company") is pleased to announce its participation in…
accessnewswire.com Lobe Sciences Ltd. Announces Closing of Upsize to Non-Brokered Private Placement NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / August 31, 2026 / Lobe Sciences Ltd. ("Lobe" or the "Company")…
accessnewswire.com Lobe Sciences Ltd. Announces Upsize to Non-Brokered Private Placement NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BC / ACCESS Newswire / August 28, 2026 / Lobe Sciences Ltd.
accessnewswire.com Lobe Sciences Expands Leadership Team with New CFO Appointment Dr. David Kideckel, PhD, MBA, joins as Chief Financial Officer, bringing nearly two decades of life sciences, capital markets and corporate advisory experience Current CFO, Mirza Rahimani,…
accessnewswire.com Lobe Sciences Ltd. Announces Closing of Non-Brokered Private Placement NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BC / ACCESS Newswire / August 20, 2026 / Lobe Sciences Ltd.
accessnewswire.com Lobe Sciences Reports Third Quarter 2026 Financial Results VANCOUVER, BC / ACCESS Newswire / August 18, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F) ("Lobe" or the "Company"), a clinical-stage biopharmaceutical company advancing…
accessnewswire.com Lobe Sciences Ltd. Announces Non-Brokered Private Placement NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BC / ACCESS Newswire / August 12, 2026 / Lobe Sciences Ltd.
accessnewswire.com Lobe Sciences Announces Results of Annual General and Special Meeting of Shareholders Shareholders Approve All Matters Presented at Meeting, Including New Long-Term Incentive Plan and Amendment to Constating Documents VANCOUVER, BC / ACCESS Newswire / August 5, 2026 / Lobe Sciences…
accessnewswire.com Lobe Sciences Files Management Information Circular for Annual General and Special Meeting on July 30, 2026 The Company's Annual General and Special Meeting will be held on Thursday, July 30, 2026, at 11:00 a.m. (Vancouver time), at 15th Floor, 1111 West Hastings Street, Vancouver, British Columbia, with…
accessnewswire.com Lobe Sciences Directors and Management Increase Equity Ownership Through Settlement of Accrued Fees by the Issuance of Common Shares Directors and management elected to receive restricted equity in place of accrued fees payable, thereby increasing ownership and further aligning with shareholders The Canadian Securities Exchange…
accessnewswire.com Lobe Sciences Announces Proposed Shares for Debt Transaction VANCOUVER, BC / ACCESS Newswire / June 1, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances high-potential drug candidates…
accessnewswire.com Lobe Sciences Ltd. Announces Participation in the D. VANCOUVER, BC / ACCESS Newswire / May 6, 2026 / Lobe Sciences Ltd. ("Lobe", or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances…
accessnewswire.com Lobe Sciences Reports Second Quarter 2026 Results and Highlights Continued Operational Progress VANCOUVER, BC / ACCESS Newswire / May 6, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F), a clinical-stage biopharmaceutical company that advances high-potential drug candidates…
accessnewswire.com Lobe Sciences Ltd. Comments on White House Executive Order Supporting Drug Development for Neurological and Mental Health Disorders VANCOUVER, BC / ACCESS Newswire / April 23, 2026 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a clinical-stage biopharmaceutical company focused on…
accessnewswire.com Lobe Sciences Ltd. Engages Massive Intelligence Pty Ltd for Investor Relations and Corporate Communications Services VANCOUVER, BC / ACCESS Newswire / April 21, 2026 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE), a clinical stage biopharmaceutical company focused on…
accessnewswire.com Lobe Sciences Ltd. Announces Closing of Non-Brokered Private Placement and Provides Corporate Update NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BC / ACCESS Newswire / April 20, 2026 / Lobe Sciences Ltd.